Impel Neuropharma raises $80M in Washington state’s first IPO of 2021 The news: Seattle-based biotech company Impel NeuroPharma raised $80 million in its initial public offering and will begin trading on… Read More
Seattle biotech scores $67.5M to treat migraines and Parkinson’s with drugs delivered deep into the nasal cavity Seattle-based biotech firm Impel NeuroPharma closed its latest round of funding, bringing in $67.5 million to develop treatments for central… Read More
